PTAKOVA, Nikola, Petr MARTINEK, Lubos HOLUBEC, Vaclav JANOVSKY, Jana VANCUROVA, Petr GROSSMANN, Paloma Alcaraz NAVARRO, Juan F. Rodriguez MORENO, Reza ALAGHEHBANDAN, Ondrej HES, Ondřej MÁJEK, Milos PESEK, Michal MICHAL and Ondrej ONDIC. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. GENES CHROMOSOMES & CANCER. HOBOKEN: WILEY-BLACKWELL, 2021, vol. 60, No 7, p. 474-481. ISSN 1045-2257. Available from: https://dx.doi.org/10.1002/gcc.22942.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database
Authors PTAKOVA, Nikola (203 Czech Republic), Petr MARTINEK (203 Czech Republic), Lubos HOLUBEC (203 Czech Republic), Vaclav JANOVSKY (203 Czech Republic), Jana VANCUROVA (203 Czech Republic), Petr GROSSMANN (203 Czech Republic), Paloma Alcaraz NAVARRO, Juan F. Rodriguez MORENO, Reza ALAGHEHBANDAN, Ondrej HES (203 Czech Republic), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Milos PESEK (203 Czech Republic), Michal MICHAL (203 Czech Republic) and Ondrej ONDIC (203 Czech Republic, guarantor).
Edition GENES CHROMOSOMES & CANCER, HOBOKEN, WILEY-BLACKWELL, 2021, 1045-2257.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.263
RIV identification code RIV/00216224:14110/21:00121773
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/gcc.22942
UT WoS 000621111200001
Keywords in English carcinoma; data drilling; ERBB; ERBB3; gene fusion; gene rearrangement; genetics; HER; HER 3; EGF‐ like domain; lung; MAPK; molecular; mRNA sequencing; neuregulin; next‐ generation sequencing; NRG1; PIK
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/6/2021 09:06.
Abstract
The fusion genes containing neuregulin-1 (NRG1) are newly described potentially actionable oncogenic drivers. Initial clinical trials have shown a positive response to targeted treatment in some cases of NRG1 rearranged lung adenocarcinoma, cholangiocarcinoma, and pancreatic carcinoma. The cost-effective large scale identification of NRG1 rearranged tumors is an open question. We have tested a data-drilling approach by performing a retrospective assessment of a de-identified molecular profiling database of 3263 tumors submitted for fusion testing. Gene fusion detection was performed by RNA-based targeted next-generation sequencing using the Archer Fusion Plex kits for Illumina (ArcherDX Inc., Boulder, CO). Novel fusion transcripts were confirmed by a custom-designed RT-PCR. Also, the aberrant expression of CK20 was studied immunohistochemically. The frequency of NRG1 rearranged tumors was 0.2% (7/3263). The most common histologic type was lung adenocarcinoma (n = 5). Also, renal carcinoma (n = 1) and prostatic adenocarcinoma (n = 1) were found. Identified fusion partners were of a wide range (CD74, SDC4, TNC, VAMP2, UNC5D), with CD74, SDC4 being found twice. The UNC5D is a novel fusion partner identified in prostate adenocarcinoma. There was no co-occurrence with the other tested fusions nor KRAS, BRAF, and the other gene mutations specified in the applied gene panels. Immunohistochemically, the focal expression of CK20 was present in 2 lung adenocarcinomas. We believe it should be considered as an incidental finding. In conclusion, the overall frequency of tumors with NRG1 fusion was 0.2%. All tumors were carcinomas. We confirm (invasive mucinous) lung adenocarcinoma as being the most frequent tumor presenting NRG1 fusion. Herein novel putative pathogenic gene fusion UNC5D-NRG1 is described. The potential role of immunohistochemistry in tumor identification should be further addressed.
PrintDisplayed: 25/5/2024 04:49